Cynthia Patton Buys Shares of Organon & Co.
Cynthia Patton acquired 17,857 shares of Organon & Co. at $13.44 each.
Key Points
- Cynthia Patton bought 17,857 shares of Organon & Co. at $13.44 per share, totaling $239,998 on June 12, 2026.
- Organon & Co. is trading near its 52-week high at $13.44, with a market cap of about $3.53 billion and a P/E ratio of 14.45.
- Other insiders, including Shalini Sharp and Philip Ozuah, also bought 17,857 shares each at the same price on June 12, 2026.
Cynthia Patton made a significant move on June 12, 2026, by purchasing 17,857 shares of Organon & Co. (NYSE: OGN) at $13.44 per share. The transaction amounted to $239,998, reflecting confidence in the company's prospects.
Insider Buying and Selling at Organon & Co.
On the same day, other insiders, including Shalini Sharp, Philip Ozuah, Ramona Sequeira, Deborah Leone, and Rochelle Lazarus, also bought 17,857 shares each at the same price. These transactions were not part of a pre-planned trading program, indicating a direct choice to invest in the company.
Organon & Co. Stock Snapshot
Shares of NYSE:OGN traded near $13.44, close to its 52-week high of $13.49. Organon & Co. has a market cap of approximately $3.53 billion and a P/E ratio of 14.45. The company's forward P/E ratio stands at 3.67, with a beta of 1.544, suggesting moderate volatility. The stock's 50-day moving average is $11.88, and its 200-day moving average is $9.04.
Recent Earnings
Organon & Co. reported revenue of $6.16 billion, though it saw a slight decline of 3.5% year-over-year. The company achieved a net margin of 3.99% and a return on equity of 34.05%. With earnings per share at $0.93, Organon is set to announce its next earnings on August 4, 2026.
Dividend
Organon & Co. offers a dividend rate of $0.08 per share, yielding 0.6%. The company's dividend payout ratio is a conservative 8.6%, indicating a stable dividend policy.
Analysts Set New Price Targets
Recent analyst activity includes BNP Paribas downgrading the stock to a hold rating with a $14 target on April 29, 2026. Piper Sandler upgraded Organon to hold with the same price target a day earlier. Barclays maintained a sell rating with an $8 target on February 24, 2026. The consensus target price is $11.25, based on four analyst opinions.
About Organon & Co.
Organon & Co., headquartered in Jersey City, New Jersey, is a global healthcare company focusing on women's health solutions. It offers a diverse portfolio of prescription therapies and medical devices across various markets, including the United States, Europe, and Asia. The company is led by CEO Joseph T. Morrissey Jr. and employs around 10,000 people.
Bottom Line
Cynthia Patton's recent purchase of Organon & Co. shares underscores a notable insider interest in the company. With a comprehensive range of healthcare products and a strong market presence, Organon remains a key player in the sector. Investors often watch insider transactions for insights, though it's important to remember that these moves are historical and may not indicate future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.